| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 测试业务(WuXi Testing)(元) | 3,018,355,999.39 | 6,539,666,743.74 | 3,091,000,383.52 | 5,718,653,382.29 | 2,605,046,406.95 |
| 国内新药研发服务部(WuXi DDSU)(元) | 257,177,952.01 | 726,452,550.24 | 341,986,707.21 | 969,629,361.59 | 455,073,160.87 |
| 化学业务(WuXi Chemistry)(元) | 12,209,866,826.82 | 29,171,488,182.59 | 13,467,202,622.69 | 28,849,731,879.85 | 12,974,122,332.78 |
| 生物学业务(WuXi Biology)(元) | 1,168,909,867.67 | 2,552,553,999.20 | 1,232,635,388.49 | 2,475,147,143.85 | 1,090,654,896.67 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(元) | 574,952,553.89 | 1,309,596,734.35 | 713,626,909.44 | 1,308,001,887.63 | 615,403,990.83 |
| 营业成本(元) | |||||
| 测试业务(WuXi Testing)(元) | 1,959,376,484.09 | 4,093,976,831.49 | 1,964,556,775.56 | 3,723,659,792.69 | - |
| 国内新药研发服务部(WuXi DDSU)(元) | 106,846,974.62 | 466,931,958.98 | 245,381,960.27 | 715,374,804.11 | - |
| 化学业务(WuXi Chemistry)(元) | 6,889,155,768.40 | 16,184,176,275.97 | 7,488,797,778.70 | 17,308,828,743.55 | - |
| 生物学业务(WuXi Biology)(元) | 747,196,887.66 | 1,522,571,429.70 | 747,414,521.74 | 1,516,087,694.92 | - |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(元) | 745,749,242.37 | 1,441,084,850.72 | 763,892,666.82 | 1,395,358,256.49 | - |
| 毛利(元) | |||||
| 测试业务(WuXi Testing)(元) | 1,058,979,515.30 | 2,445,689,912.25 | 1,126,443,607.96 | 1,994,993,589.60 | - |
| 国内新药研发服务部(WuXi DDSU)(元) | 150,330,977.39 | 259,520,591.26 | 96,604,746.94 | 254,254,557.48 | - |
| 化学业务(WuXi Chemistry)(元) | 5,320,711,058.42 | 12,987,311,906.62 | 5,978,404,843.99 | 11,540,903,136.30 | - |
| 生物学业务(WuXi Biology)(元) | 421,712,980.01 | 1,029,982,569.50 | 485,220,866.75 | 959,059,448.93 | - |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(元) | -170,796,688.48 | -131,488,116.37 | -50,265,757.38 | -87,356,368.86 | - |
| 毛利率(%) | |||||
| 测试业务(WuXi Testing)(%) | 35.08 | 37.40 | 36.44 | 34.89 | - |
| 国内新药研发服务部(WuXi DDSU)(%) | 58.45 | 35.72 | 28.25 | 26.22 | - |
| 化学业务(WuXi Chemistry)(%) | 43.58 | 44.52 | 44.39 | 40.00 | - |
| 生物学业务(WuXi Biology)(%) | 36.08 | 40.35 | 39.36 | 38.75 | - |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(%) | -29.71 | -10.04 | -7.04 | -6.68 | - |
| 收入构成(%) | |||||
| 测试业务(WuXi Testing)(%) | 17.52 | 16.23 | 16.40 | 14.54 | 14.68 |
| 国内新药研发服务部(WuXi DDSU)(%) | 1.49 | 1.80 | 1.81 | 2.47 | 2.57 |
| 化学业务(WuXi Chemistry)(%) | 70.87 | 72.39 | 71.46 | 73.37 | 73.13 |
| 生物学业务(WuXi Biology)(%) | 6.78 | 6.33 | 6.54 | 6.29 | 6.15 |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(%) | 3.34 | 3.25 | 3.79 | 3.33 | 3.47 |
| 毛利构成(%) | |||||
| 测试业务(WuXi Testing)(%) | 15.62 | 14.74 | 14.75 | 13.61 | - |
| 国内新药研发服务部(WuXi DDSU)(%) | 2.22 | 1.56 | 1.27 | 1.73 | - |
| 化学业务(WuXi Chemistry)(%) | 78.47 | 78.28 | 78.29 | 78.71 | - |
| 生物学业务(WuXi Biology)(%) | 6.22 | 6.21 | 6.35 | 6.54 | - |
| 细胞及基因疗法CTDMO业务(WuXi ATU)(%) | -2.52 | -0.79 | -0.66 | -0.60 | - |